{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:28:10Z","timestamp":1776878890296,"version":"3.51.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Flubendazole was shown to exert anti-leukaemia and anti-myeloma activity through inhibition of microtubule function. Here, flubendazole was tested for its effects on the viability of in total 461 cancer cell lines. Neuroblastoma was identified as highly flubendazole-sensitive cancer entity in a screen of 321 cell lines from 26 cancer entities. Flubendazole also reduced the viability of five primary neuroblastoma samples in nanomolar concentrations thought to be achievable in humans and inhibited vessel formation and neuroblastoma tumour growth in the chick chorioallantoic membrane assay. Resistance acquisition is a major problem in high-risk neuroblastoma. 119 cell lines from a panel of 140 neuroblastoma cell lines with acquired resistance to various anti-cancer drugs were sensitive to flubendazole in nanomolar concentrations. Tubulin-binding agent-resistant cell lines displayed the highest flubendazole IC<jats:sub>50<\/jats:sub>and IC<jats:sub>90<\/jats:sub>values but differences between drug classes did not reach statistical significance. Flubendazole induced p53-mediated apoptosis. The siRNA-mediated depletion of the p53 targets p21, BAX, or PUMA reduced the neuroblastoma cell sensitivity to flubendazole with PUMA depletion resulting in the most pronounced effects. The MDM2 inhibitor and p53 activator nutlin-3 increased flubendazole efficacy while RNAi-mediated p53-depletion reduced its activity. In conclusion, flubendazole represents a potential treatment option for neuroblastoma including therapy-refractory cells.<\/jats:p>","DOI":"10.1038\/srep08202","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T10:02:37Z","timestamp":1422957757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen"],"prefix":"10.1038","volume":"5","author":[{"given":"Martin","family":"Michaelis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bishr","family":"Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Rothweiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"L\u00f6schmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Voges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Mittelbronn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Starzetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick N.","family":"Harter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnaz A.","family":"Abhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Fulda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Westermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristoffer","family":"Riecken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Spek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wiese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm G.","family":"Dirks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Zehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark N.","family":"Wass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"jr.","given":"Jindrich","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"BFsrep08202_CR1","first-page":"2963","volume":"8","author":"T Mukhopadhyay","year":"2002","unstructured":"Mukhopadhyay, T., Sasaki, J., Ramesh, R. & Roth, J. A. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 8, 2963\u20132969 (2002).","journal-title":"Clin Cancer Res."},{"key":"BFsrep08202_CR2","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","volume":"115","author":"PA Spagnuolo","year":"2010","unstructured":"Spagnuolo, P. A. et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 115, 4824\u20134833 (2010).","journal-title":"Blood"},{"key":"BFsrep08202_CR3","first-page":"1201","volume":"1","author":"J Sasaki","year":"2002","unstructured":"Sasaki, J. et al. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol. Cancer Ther. 1, 1201\u20131209 (2002).","journal-title":"Mol. Cancer Ther."},{"key":"BFsrep08202_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/1541-7786.MCR-07-2159","volume":"6","author":"N Doudican","year":"2008","unstructured":"Doudican, N., Rodriguez, A., Osman, I. & Orlow, S. J. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol. Cancer Res. 6, 1308\u20131315 (2008).","journal-title":"Mol. Cancer Res."},{"key":"BFsrep08202_CR5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00280-007-0538-0","volume":"61","author":"D Martarelli","year":"2008","unstructured":"Martarelli, D., Pompei, P., Baldi, C. & Mazzoni, G. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother. Pharmacol. 61, 809\u2013817 (2008).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFsrep08202_CR6","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/neuonc\/nor077","volume":"13","author":"RY Bai","year":"2011","unstructured":"Bai, R. Y., Staedtke, V., Aprhys, C. M., Gallia, G. L. & Riggins, G. J. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 13, 974\u2013982 (2011).","journal-title":"Neuro Oncol."},{"key":"BFsrep08202_CR7","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s00432-013-1539-5","volume":"139","author":"P Nygren","year":"2013","unstructured":"Nygren, P., Frykn\u00e4s, M., Agerup, B. & Larsson, R. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J. Cancer Res. Clin. Oncol. 139, 2133\u20132140 (2013).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"BFsrep08202_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.parint.2009.07.006","volume":"58","author":"L Ceballos","year":"2009","unstructured":"Ceballos, L. et al. Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice. Parasitol. Int. 58, 354\u2013358 (2009).","journal-title":"Parasitol. Int."},{"key":"BFsrep08202_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2307\/3001968","volume":"1","author":"F Wilcoxon","year":"1945","unstructured":"Wilcoxon, F. Individual Comparisons by Ranking Methods. Biometrics Bulletin 1, 80\u201383 (1945).","journal-title":"Biometrics Bulletin"},{"key":"BFsrep08202_CR10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B 57, 289\u2013300 (1995).","journal-title":"J. R. Statist. Soc. B"},{"key":"BFsrep08202_CR11","first-page":"173","volume":"2","author":"L Chen","year":"2012","unstructured":"Chen, L. & Tweddle, D. A. p53, SKP2 and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance. Front. Oncol. 2, 173 (2012).","journal-title":"Front. Oncol."},{"key":"BFsrep08202_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nrc2803","volume":"10","author":"M Kavallaris","year":"2010","unstructured":"Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10, 194\u2013204 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"BFsrep08202_CR13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet, C. & Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9, 790\u2013803 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFsrep08202_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szak\u00e1cs","year":"2006","unstructured":"Szak\u00e1cs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. & Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219\u2013234 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFsrep08202_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.drudis.2007.12.010","volume":"13","author":"G Szak\u00e1cs","year":"2008","unstructured":"Szak\u00e1cs, G., V\u00e1radi, A., Ozvegy-Laczka, C. & Sarkadi, B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today 13, 379\u2013393 (2008).","journal-title":"Drug Discov. Today"},{"key":"BFsrep08202_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1158\/0008-5472.CAN-08-1856","volume":"69","author":"M Michaelis","year":"2009","unstructured":"Michaelis, M. et al. Reversal of P-glycoprotein-mediated multi-drug resistance by the MDM2 antagonist nutlin-3. Cancer Res. 69, 416\u2013421 (2009).","journal-title":"Cancer Res."},{"key":"BFsrep08202_CR17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1593\/neo.10856","volume":"12","author":"F Rothweiler","year":"2010","unstructured":"Rothweiler, F. et al. Anti-cancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multi-drug resistant cancer cells. Neoplasia 12, 1023\u20131030 (2010).","journal-title":"Neoplasia"},{"key":"BFsrep08202_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00280-006-0244-3","volume":"59","author":"V Jekerle","year":"2007","unstructured":"Jekerle, V., Klinkhammer, W., Reilly, R. M., Piquette-Miller, M. & Wiese, M. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. Cancer Chemother. Pharmacol. 59, 61\u201369 (2007).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFsrep08202_CR19","doi-asserted-by":"publisher","first-page":"6376","DOI":"10.1158\/1078-0432.CCR-08-1526","volume":"14","author":"EA Bassett","year":"2008","unstructured":"Bassett, E. A., Wang, W., Rastinejad, F. & El-Deiry, W. S. Structural and functional basis for therapeutic modulation of p53 signaling. Clin. Cancer Res. 14, 6376\u20136386 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFsrep08202_CR20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844\u2013848 (2004).","journal-title":"Science"},{"key":"BFsrep08202_CR21","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ajpath.2011.12.011","volume":"180","author":"M Michaelis","year":"2012","unstructured":"Michaelis, M. et al. Chemotherapy-associated angiogenesis in neuroblastoma tumors. Am. J. Pathol. 180, 1370\u20131377 (2012).","journal-title":"Am. J. Pathol."},{"key":"BFsrep08202_CR22","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202\u20132211 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep08202_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.bcp.2007.05.006","volume":"74","author":"A Khalilzadeh","year":"2007","unstructured":"Khalilzadeh, A., Wangoo, K. T., Morris, D. L. & Pourgholami, M. H. Epothilone-paclitaxel resistant leukemic cells CEM\/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways. Biochem. Pharmacol. 74, 407\u2013414 (2007).","journal-title":"Biochem. Pharmacol."},{"key":"BFsrep08202_CR24","first-page":"3791","volume":"29","author":"SW Chu","year":"2009","unstructured":"Chu, S. W., Badar, S., Morris, D. L. & Pourgholami, M. H. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res. 29, 3791\u20133796 (2009).","journal-title":"Anticancer Res."},{"key":"BFsrep08202_CR25","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/CAD.0b013e3283648c69","volume":"24","author":"V Kr\u00e1lov\u00e1","year":"2013","unstructured":"Kr\u00e1lov\u00e1, V. et al. Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole and flubendazole in intestinal cancer cell lines. Anticancer Drugs 24, 911\u2013919 (2013).","journal-title":"Anticancer Drugs"},{"key":"BFsrep08202_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0304-3835(03)00088-0","volume":"197","author":"DA Tweddle","year":"2003","unstructured":"Tweddle, D. A. et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 197, 93\u201398 (2003).","journal-title":"Cancer Lett."},{"key":"BFsrep08202_CR27","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1158\/1078-0432.CCR-09-1865","volume":"16","author":"J Carr-Wilkinson","year":"2010","unstructured":"Carr-Wilkinson, J. et al. High Frequency of p53\/MDM2\/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin. Cancer Res. 16, 1108\u20131118 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFsrep08202_CR28","first-page":"1029","volume":"27","author":"R Kotchetkov","year":"2005","unstructured":"Kotchetkov, R. et al. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp Expression. Int. J. Oncol. 27, 1029\u20131037 (2005).","journal-title":"Int. J. Oncol."},{"key":"BFsrep08202_CR29","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1038\/cddis.2011.129","volume":"2","author":"M Michaelis","year":"2011","unstructured":"Michaelis, M. et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug resistant cancer cells. Cell. Death Dis. 2, e243 (2011).","journal-title":"Cell. Death Dis."},{"key":"BFsrep08202_CR30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/1096-911X(20001201)35:6<563::AID-MPO15>3.0.CO;2-J","volume":"35","author":"N Keshelava","year":"2000","unstructured":"Keshelava, N., Zuo, J. J., Waidyaratne, N. S., Triche, T. J. & Reynolds, C. P. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med. Pediatr. Oncol. 35, 563\u2013568 (2000).","journal-title":"Med. Pediatr. Oncol."},{"key":"BFsrep08202_CR31","first-page":"6185","volume":"61","author":"N Keshelava","year":"2001","unstructured":"Keshelava, N. et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 61, 6185\u20136193 (2001).","journal-title":"Cancer Res."},{"key":"BFsrep08202_CR32","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1093\/nar\/gkl619","volume":"34","author":"D Goldschneider","year":"2006","unstructured":"Goldschneider, D. et al. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res. 34, 5603\u20135612 (2006).","journal-title":"Nucleic Acids Res."},{"key":"BFsrep08202_CR33","doi-asserted-by":"publisher","first-page":"10351","DOI":"10.1158\/0008-5472.CAN-06-4345","volume":"67","author":"C Xue","year":"2007","unstructured":"Xue, C. et al. p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res. 67, 10351\u201310360 (2007).","journal-title":"Cancer Res."},{"key":"BFsrep08202_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1746-6148-8-71","volume":"8","author":"L Ceballos","year":"2012","unstructured":"Ceballos, L., Moreno, L., Torrado, J. J., Lanusse, C. & Alvarez, L. Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution. BMC Vet. Res. 8, 71 (2012).","journal-title":"BMC Vet. Res."},{"key":"BFsrep08202_CR35","doi-asserted-by":"publisher","first-page":"6832","DOI":"10.1021\/jm300576q","volume":"55","author":"S Dakshanamurthy","year":"2012","unstructured":"Dakshanamurthy, S. et al. Predicting new indications for approved drugs using a proteochemometric method. J. Med. Chem. 55, 6832\u20136848 (2012).","journal-title":"J. Med. Chem."},{"key":"BFsrep08202_CR36","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.4158\/EP10390.CR","volume":"17","author":"IY Dobrosotskaya","year":"2011","unstructured":"Dobrosotskaya, I. Y., Hammer, G. D., Schteingart, D. E., Maturen, K. E. & Worden, F. P. Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. Endocr. Pract. 17, e59\u201362 (2011).","journal-title":"Endocr. Pract."},{"key":"BFsrep08202_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/0284186X.2013.844359","volume":"53","author":"P Nygren","year":"2014","unstructured":"Nygren, P. & Larsson, R. Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer. Acta Oncol. 53, 427\u2013428 (2014).","journal-title":"Acta Oncol."},{"key":"BFsrep08202_CR38","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1158\/1078-0432.CCR-05-1181","volume":"12","author":"MH Pourgholami","year":"2006","unstructured":"Pourgholami, M. H., Yan Cai, Z., Lu, Y., Wang, L. & Morris, D. L. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin. Cancer Res. 12, 1928\u20131935 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFsrep08202_CR39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00280-009-1157-8","volume":"65","author":"MH Pourgholami","year":"2010","unstructured":"Pourgholami, M. H. et al. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Cancer Chemother. Pharmacol. 65, 597\u2013605 (2010).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFsrep08202_CR40","first-page":"185","volume":"39","author":"H Feldmeier","year":"1982","unstructured":"Feldmeier, H., Bienzle, U., D\u00f6hring, E. & Dietrich, M. Flubendazole versus mebendazole in intestinal helminthic infections. Acta Trop. 39, 185\u2013189 (1982).","journal-title":"Acta Trop."},{"key":"BFsrep08202_CR41","first-page":"314","volume":"8","author":"A Lass\u00e8gue","year":"1984","unstructured":"Lass\u00e8gue, A. et al. Traitement de \u013a\u00e9chinococcose alv\u00e9olaire humaine par le flubendazole: \u00e9tude clinique, morphologique et immunologique. Gastroenterol. Clin. Biol. 8, 314\u2013320 (1984).","journal-title":"Gastroenterol. Clin. Biol."},{"key":"BFsrep08202_CR42","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4269\/ajtmh.1984.33.627","volume":"33","author":"E T\u00e9llez-Gir\u00f3n","year":"1984","unstructured":"T\u00e9llez-Gir\u00f3n, E. et al. Treatment of neurocysticercosis with flubendazole. Am. J. Trop. Med. Hyg. 33, 627\u2013631 (1984).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"BFsrep08202_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/ijc.10917","volume":"104","author":"R Kotchetkov","year":"2003","unstructured":"Kotchetkov, R. et al. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int. J. Cancer 104, 36\u201343 (2003).","journal-title":"Int. J. Cancer"},{"key":"BFsrep08202_CR44","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/mt.2008.6","volume":"16","author":"K Weber","year":"2008","unstructured":"Weber, K., Bartsch, U., Stocking, C. & Fehse, B. A multicolor panel of novel lentiviral \u201cgene ontology\u201d (LeGO) vectors for functional gene analysis. Mol. Ther. 16, 698\u2013706 (2008).","journal-title":"Mol. Ther."},{"key":"BFsrep08202_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/gt.2009.149","volume":"17","author":"K Weber","year":"2010","unstructured":"Weber, K., Mock, U., Petrowitz, B., Bartsch, U. & Fehse, B. Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis. Gene Ther. 17, 511\u2013520 (2010).","journal-title":"Gene Ther."},{"key":"BFsrep08202_CR46","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/cgt.2011.68","volume":"19","author":"F Durupt","year":"2012","unstructured":"Durupt, F. et al. The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses. Cancer Gene Ther. 19, 58\u201368 (2012).","journal-title":"Cancer Gene Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep08202","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep08202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep08202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:07:35Z","timestamp":1717718855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep08202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,7,15]]}},"alternative-id":["BFsrep08202"],"URL":"https:\/\/doi.org\/10.1038\/srep08202","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,3]]},"assertion":[{"value":"1 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8202"}}